Company intelligence / Profile preview
Artificial Cell Technologies
New Haven, Connecticut, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Lead vaccine candidates for malaria and RSV are in pre-clinical development using a synthetic multilayer nanofilm platform, with a planned Phase 1 malaria trial (as of 2017); to date, animal studies indicate high immunogenicity, strong safety, and no adjuvant required[1][3][5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- NanoparticleBiologicSynthetic vaccine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Artificial Cell Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Artificial Cell Technologies.